Divalproex Sodium Tablet, Delayed Release
Product Images NDC 55154-0577

6 FDA label images from Cardinal Health 107, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 55154-0577). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Spl-divalproex-structure (Spl Divalproex Structure)
Chemical structure diagram of divalproex sodium, illustrating its molecular arrangement including sodium ions and carbon chains as part of the compound.*
FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)
A bar graph titled Figure 1 comparing percentages between treatment groups in two studies. The y-axis shows percentages from 0% to 70%. Study 1 (YMRS) compares PBO at 26% to DVPX at 60%, and Study 2 (MRS) compares PBO at 29% to DVPX at 58%. Asterisks indicate statistical significance for DVPX groups.*
FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)
A cumulative distribution graph showing the percentage reduction in CPS (Clinical Parameter Score) rate on the y-axis versus the percentage of patients on the x-axis for Divalproex Sodium (DVPX) compared to a placebo. The graph compares improvement and worsening between the treatment and placebo groups.*
FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)
Figure 3 is an empirical cumulative distribution function (ECDF) plot illustrating the percentage reduction in CPS rate among patients treated with Divalproex Sodium. The graph compares high dose (solid line) and low dose (dashed line) groups, showing the distribution of patient improvement, no change, or worsening in CPS rate across percentages of patients from 0 to 100.*
FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)
A bar chart titled 'Figure 4 Mean 4-week Migraine Rates' comparing migraine rates for placebo and Divalproex Sodium (DVPX) groups in two studies. The vertical axis represents migraine rates ranging from 0 to 6. Study 1 shows higher migraine rates for placebo compared to DVPX. Study 2 similarly shows higher migraine rates for placebo versus DVPX.*
FDA Label Image

500mg Bag Label (1004e77e B572 4d39 8ddd 5325612dad7b 00)

500mg Bag Label (1004e77e B572 4d39 8ddd 5325612dad7b 00)
Label for Divalproex Sodium delayed-release tablets, USP 500 mg, in a package of 10 tablets. Each pink coated tablet is imprinted with '798' in black ink on one side. The label includes storage instructions, a barcode, and states the product is for oral use and prescription only. Packaged by Major Pharmaceuticals and distributed by Cardinal Health 107, LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.